• Citer

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

par Tolaney, Sara S.M.;Winer, Eric E.P.;Nechushtan, Hovav;Ron, Ilan Gil;Schöffski, Patrick;Awada, Ahmad ;Yasenchak, Christopher C.A.;Laird, Alexander Douglas;O’Keeffe, Bridget;Shapiro, Geoffrey G.I.
Référence Breast cancer research and treatment, 160, 2, page (305-312)
Publication Publié, 2016-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Auteur:	Tolaney, Sara S.M.; Winer, Eric E.P.; Nechushtan, Hovav; Ron, Ilan Gil; Schöffski, Patrick; Awada, Ahmad; Yasenchak, Christopher C.A.; Laird, Alexander Douglas; O’Keeffe, Bridget; Shapiro, Geoffrey G.I.
Informations sur la publication:	Breast cancer research and treatment, 160, 2, page (305-312)
Statut de publication:	Publié, 2016-11
Sujet CREF:	Cancérologie
Mots-clés:	Cabozantinib
	Metastatic breast cancer
	Overall survival
	Progression-free survival
	Tumor response
	Vascular endothelial growth factor receptor
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6806
	info:doi/10.1007/s10549-016-4001-y
	info:scp/84990842006